BSX stock forecast, quote, news & analysis
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts... Show more
Boston Scientific (BSX) Stock Analysis: Watchman Slowdown Triggers Broad Growth Reset
Key Takeaways
- Boston Scientific shares have remained relatively rangebound near the $42–$45 level over the last 30 days, following a prolonged decline of more than 60% from the 52-week high of $109.50 set in September 2025.
- The company cut full-year 2026 organic revenue growth guidance to 6.5%–8%, down from a prior range of 10%–11%, driven primarily by weaker-than-expected WATCHMAN heart implant volumes and softening trends in electrophysiology and urology.
- Wall Street analysts maintain a predominantly bullish stance with a consensus "Moderate Buy" rating and an average 12-month price target near $72, implying significant upside from current levels despite meaningful downward target revisions in recent weeks.
- The company's Q2 2026 earnings report, scheduled for July 29, is widely seen as a pivotal event that could either stabilize sentiment or trigger a further reset in expectations.
- A $5 billion share repurchase authorization and the planned $14.5 billion acquisition of Penumbra signal management's long-term confidence, though the combination adds financial leverage at a sensitive moment.
Current Market Snapshot
Boston Scientific Corporation (BSX) has weathered one of the most challenging stretches in its recent history. After reaching an all-time high of $109.50 in September 2025, the stock has shed roughly 60% of its value as a series of guidance cuts, competitive pressures, and a significant growth deceleration in its flagship WATCHMAN franchise repriced investor expectations. Over the past 30 days, shares have traded in a relatively tight band between approximately $42.25 and $45.30, reflecting a market that is largely awaiting the next catalyst — most immediately, the company's second-quarter earnings release on July 29, 2026.
Despite the stock's steep decline, institutional ownership remains elevated at roughly 89%, and the broader analyst community continues to view Boston Scientific's diversified medical device portfolio as undervalued relative to its long-term earnings power. The stock currently trades at a forward P/E multiple in the low-to-mid teens, a significant discount to its historical premium and to the broader medtech peer group.
Boston Scientific (BSX) Business Overview and Competitive Position
Founded in 1979 and headquartered in Marlborough, Massachusetts, Boston Scientific is one of the world's largest medical technology companies, specializing in minimally invasive devices used across interventional cardiology, electrophysiology, endoscopy, urology, neuromodulation, and peripheral interventions. The company generates roughly half of its revenue outside the United States, maintaining a truly global commercial footprint.
The company's most prominent growth franchise has been WATCHMAN, a left atrial appendage closure device used in patients with atrial fibrillation who cannot tolerate long-term blood thinners. Beyond WATCHMAN, Boston Scientific competes aggressively in the electrophysiology market with its FARAPULSE pulsed-field ablation system, in endoscopy with gastrointestinal and pulmonary tools, and in neuromodulation with spinal cord and deep brain stimulation devices. The pending $14.5 billion acquisition of Penumbra, a neurovascular intervention specialist, underscores the company's ambition to expand into high-growth adjacent markets such as stroke care. This breadth across procedural medicine has historically provided Boston Scientific with diversification advantages, though recent weakness across multiple segments simultaneously has tested that thesis.
Recent Developments Driving BSX
The most consequential development of the past 30 days has been the market's continued digestion of the WATCHMAN growth reset. At Bernstein's Strategic Decisions Conference in late May, CEO Mike Mahoney disclosed that U.S. WATCHMAN sales would be flat sequentially in both the second and third quarters, citing physician workflow constraints and declining standalone procedure volumes. Management subsequently lowered full-year organic growth guidance to 6.5%–8%, down sharply from 10%–11%, triggering a wave of analyst price-target reductions.
In July alone, Needham lowered its target to $57 from $77, Evercore ISI trimmed to $65 from $78, Mizuho cut to $70 from $90, and Truist reduced to $64 from $85 — all while maintaining Buy or Outperform ratings. Wolfe Research downgraded the stock to Peer Perform, while Weiss Ratings moved to a Sell rating. Analyst consensus still points to a Moderate Buy, but the trajectory of estimate revisions has been unmistakably negative.
Adding complexity, Boston Scientific announced several Class II recalls related to CRE and CRE Pro Wireguided endoscopy devices due to potential sterile packaging breaches, raising fresh concerns about quality-control oversight. On the capital allocation front, the board authorized a $5 billion share repurchase program, and the company confirmed plans to acquire Penumbra in a cash-and-stock transaction valued at approximately $14.5 billion — its largest deal in two decades. While strategically ambitious, the transaction arrives at a moment when the core business is already navigating a growth slowdown and significantly increases leverage.
Q1 2026 results, reported in April, actually beat expectations with adjusted EPS of $0.80 on revenue of $5.20 billion, representing 11.6% year-over-year growth. The challenge for the stock has not been backward-looking performance but rather forward-looking guidance that has repeatedly disappointed. All eyes are now on the July 29 Q2 report, where consensus estimates call for EPS of $0.83 on revenue of $5.39 billion.
Trending AI Robots
In a fast-moving market environment like today's, traders are increasingly turning to AI-driven tools to identify opportunities and manage risk across thousands of stocks. Tickeron's Trending AI Robots page showcases a curated selection of the platform's top-performing AI trading bots, drawn from a universe of hundreds of bots that actively trade across a wide range of tickers. Each bot operates with its own distinct strategy, timeframe, and performance metrics — from short-term momentum plays to longer-duration swing strategies — giving users visibility into which approaches are currently generating the strongest results. The Trending section highlights only those bots demonstrating the most relevant and consistent performance, helping traders quickly identify AI-powered strategies aligned with current market conditions.
2026 Outlook and What Investors Should Watch
The second half of 2026 will be defined by whether Boston Scientific can demonstrate stabilization in its core growth franchises. The Q2 earnings report on July 29 is the next major checkpoint, with investors closely monitoring WATCHMAN volume trends, electrophysiology momentum — particularly FARAPULSE adoption — and urology segment performance. Any further downward revision to full-year guidance would likely extend the stock's underperformance, while even a modest beat-and-maintain outcome could trigger relief buying given the deeply discounted valuation.
Beyond earnings, the Penumbra acquisition's integration planning and regulatory approval timeline will shape sentiment through year-end. The deal's strategic logic in neurovascular intervention is widely acknowledged, but execution risk and balance-sheet implications remain open questions. Additionally, macroeconomic factors — including potential policy changes affecting medical device reimbursement, hospital capital spending trends, and currency headwinds from a strong U.S. dollar — will continue to influence the investment case. With 26 out of 30 analysts maintaining Buy-equivalent ratings, the market is clearly pricing in a recovery scenario, but that recovery will need to be supported by tangible operational evidence in the quarters ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Momentum Indicator for BSX turns positive, indicating new upward trend
BSX saw its Momentum Indicator move above the 0 level on July 27, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at .
Technical Analysis (Indicators)
Bullish Trend Analysis
BSX moved above its 50-day moving average on July 31, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for BSX crossed bullishly above the 50-day moving average on August 05, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 15 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in of 338 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for BSX moved out of overbought territory on August 05, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 46 similar instances where the indicator moved out of overbought territory. In of the 46 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 8 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
BSX broke above its upper Bollinger Band on August 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BSX entered a downward trend on July 24, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.933) is normal, around the industry mean (10.714). P/E Ratio (20.429) is within average values for comparable stocks, (68.853). Projected Growth (PEG Ratio) (0.725) is also within normal values, averaging (3.950). BSX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.016). P/S Ratio (3.582) is also within normal values, averaging (36.904).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices